Monitor the progress of the Phase 3 VERSATILE-003 trial and upcoming catalysts, including PFS data readout in 2Q 2026 and final data readout in 1H 2027. The positive clinical data could lead to increased investor interest and potential partnerships.
Price Chart
Executive Summary
PDS Biotechnology updated its corporate presentation deck, which includes positive clinical trial data for its lead compound PDS0101 in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer. The presentation highlights a median overall survival of 39.3 months and a 77.4% disease control rate, which is significantly better than the 12-18 month benchmark with current standard of care.
Key Facts
- PDS Biotechnology updated its corporate presentation deck on April 24, 2026
- The presentation highlights clinical data for PDS0101 in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer
- The trial showed a median overall survival of 39.3 months, compared to a 12-18 month benchmark with current standard of care
- The disease control rate was 77.4%
- The company has a Phase 3 pivotal trial (VERSATILE-003) underway with FDA alignment on the primary endpoint for accelerated approval
- The presentation also highlights the company's global IP portfolio with PDS0101 exclusivity through 2041/2042
Financial Impact
The positive clinical data could significantly increase the company's valuation, especially if the Phase 3 trial is successful. The total addressable market in the US is estimated at $1.0B for HPV16+ HNSCC.
Risk Factors
- The company is a clinical-stage biotech with no approved products, so it is highly dependent on the success of its clinical trials
- The company may need additional financing to fund its operations, which could lead to dilution
- The company's ability to protect its intellectual property is a key risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-016684 |
| Document: ef20071434_8k.htm | 0001140361-26-016684 |
| Document: 0001140361-26-016684-index-headers.html | 0001140361-26-016684 |
| Document: 0001140361-26-016684-index.html | 0001140361-26-016684 |
| Document: 0001140361-26-016684.txt | 0001140361-26-016684 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $0.3000 $0.5853 | ▼ −95.10% | ▼ −96.22% | $0.7366 (−145.53%) |
Aug 19, 2026 6w ago | 8-K | $0.2089 $0.2179 | ▲ +4.31% | ▲ +3.19% | $0.7366 (+252.61%) |
Aug 13, 2026 7w ago | 8-K | $0.2332 $0.2089 | ▲ +10.42% | ▲ +8.46% | $0.7366 (−215.87%) |
Aug 11, 2026 7w ago | 8-K | $0.2570 $0.2080 | ▲ +19.07% | ▲ +18.66% | $0.7366 (−186.61%) |
Jul 22, 2026 10w ago | EFFECT | $0.7155 $0.6696 | ▲ +6.42% | ▲ +4.01% | $0.7366 (−2.95%) |
Jun 26, 2026 13w ago | DEFA14A | $0.8991 $0.8461 | ▼ −5.89% | ▼ −7.28% | $0.7366 (−18.07%) |
Jun 15, 2026 15w ago | 8-K | $0.9600 $0.9120 | ▲ +5.00% | ▲ +2.77% | $0.7366 (+23.27%) |
Jun 15, 2026 15w ago | 8-K | $1.02 $0.9412 | ▼ −7.73% | ▼ −6.34% | $0.7366 (−27.78%) |
Jun 2, 2026 17w ago | 8-K | $1.16 $1.03 | ▼ −11.21% | ▼ −8.24% | $0.7366 (−36.50%) |
May 13, 2026 20w ago | Press Release | $1.33 $1.00 | ▼ −24.81% | ▼ −23.65% | $0.7366 (−44.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access